艾司洛尔联合胺碘酮治疗急性心肌梗死伴高危快速室性心律失常的临床研究  

Clinical study on the esmolol combined with amiodarone in the treatment of acute myocardial infarction with high-risk rapid ventricular arrhythmia

作　　者：谷祥任 Gu Xiangren(The First Department of Cardiology,the People's Hospital of Zhangjiajie City,Hunan Zhangjiajie 427000)

机构地区：[1]张家界市人民医院心内一科,湖南张家界427000

出　　处：《中国社区医师》2020年第21期32-32,34,共2页Chinese Community Doctors

摘　　要：目的:探讨艾司洛尔联合胺碘酮治疗急性心肌梗死伴高危快速室性心律失常的临床效果。方法:2017年1月-2019年8月收治急性心肌梗死伴高危快速室性心律失常患者98例,随机分为两组,各49例。对照组采用胺碘酮治疗;试验组采用胺碘酮联合艾司洛尔治疗。比较两组治疗效果。结果:试验组治疗总有效率高于对照组,病死率与室颤发生率均低于对照组,差异有统计学意义(P<0.05)。结论:胺碘酮联合艾司洛尔治疗急性心肌梗死伴高危快速室性心律失常,能够提高临床疗效,有利于降低病死率与室颤率,且用药安全可靠。Objective:To investigate the clinical effect of esmolol combined with amiodarone in the treatment of acute myocardial infarction with high-risk rapid ventricular arrhythmia.Methods:From January 2017 to August 2019,98 patients with acute myocardial infarction with high-risk rapid ventricular arrhythmia were selected,they were randomly divided into two groups with49 cases in each group.The control group was treated with amiodarone.The experimental group was treated with esmolol combined with amiodarone.The therapeutic effects of the two groups were compared.Results:The total effective rate of treatment in the experimental group was higher than the control group,the mortality and incidence of ventricular fibrillation were lower than the control group,the differences were statistically significant(P<0.05).Conclusion:Esmolol combined with amiodarone in the treatment of acute myocardial infarction with high-risk rapid ventricular arrhythmia can improve the clinical efficacy,it is conducive to reduce the case fatality rate and ventricular fibrillation rate,and the medication is safe and reliable.

关 键 词：急性心肌梗死 室性心律失常 艾司洛尔 胺碘酮 

分 类 号：R541.7[医药卫生—心血管疾病] R542.22[医药卫生—内科学]